PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Raze Therapeutics, Inc.

USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Raze ranks #33,012 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.

#33,012
of 49,997 US assignees by volume
36th percentile
by Innovation Score (30.9/100)
16.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R33012 · US Corporation #33,012 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 8 grants
  • MID-PACK #33,012/49,997
  • PHOTO-FINISH Ramscor
  • CPC-NARROW A61P · 4 areas
  • INNOV-THIN 30.9/100
  • CLAIMS-RICH 16.0 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Ramscor, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Raze’s 30.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Raze

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Raze's Innovation Score is 30.9/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Raze?

Each dot is one of Raze’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Raze’s own 16.0 claims/patent is at or below the 17.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Raze vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.088.1 510152025 Granted patents (volume) Avg claims / patent Ramscor, Inc. - 8, 8.62RamscorRaptor Technologies LLC - 8, 17.62RaptorRaute Oyj - 8, 14.5Raute OyjRaycast Systems, Inc. - 8, 20.12Raycast SystemsReVision Optics, Inc. - 8, 11.25Revision OpticsReckitt Benckiser (UK) Limited - 8, 19.38Reckitt Benckiser…Recommind, Inc. - 8, 20.62RecommindRecorded Future, Inc. - 8, 20.62Recorded FutureRaze Therapeutics, Inc. - 8, 16Raze Therapeutics
Raze vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Raze's grants concentrate

Raze Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2023. By volume, Raze sits between Ramscor, Inc. and Recorded Future, Inc..

Raze's three-year grant acceleration

Raze Therapeutics, Inc. shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Raze's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Raze holds 8 patents at rank #33,052, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Raze

By rank, the assignees closest to #33,052 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Raze's primary technology class.

Raze's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 2021202220232025 2
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Raze Therapeutics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 3 37.5%
2022 2 25.0%
2023 1 12.5%
2025partial year 2 25.0%

Which technologies does Raze Therapeutics, Inc. patent most?

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Raze Therapeutics, Inc.'s patent record in context - here's where to go next.

  • Raze Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #33,012 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Raze Therapeutics, Inc. against Ramscor, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 30.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.